XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 6 - Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2014

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,					Nine Months Ended September 30,
	2014			2013		2014			2013
	(in thousands)
Net revenues:
Finished pharmaceutical products	$	53,729		$	59,318	$	148,500		$	174,805
API		5,982			—		6,084			—
Total net revenues		59,711			59,318		154,584			174,805

Gross Profit:
Finished pharmaceutical products		12,122			20,280		39,592			67,327
API		(331	)		—		(296	)		—
Total gross profit		11,791			20,280		39,296			67,327

Operating expenses		19,608			20,054		50,255			52,767

Income (loss) from operations		(7,817	)		226		(10,959	)		14,560
Non-operating income (expenses)		(167	)		109		(1,372	)		(115	)

Income (loss) before income taxes	$	(7,984	)	$	335	$	(12,331	)	$	14,445

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	Net Revenue						Net Revenue						Long-Lived Assets
	Three Months Ended September 30,						Nine Months Ended September 30,						September 30,			December 31,
	2014			2013			2014			2013			2014			2013
	(in thousands)
U.S.		$	53,729		$	59,318		$	148,500		$	174,805		$	98,744		$	99,398
China			—			—			—			—			21,011			17,221
France			5,982			—			6,084			—			14,357			—
Total		$	59,711		$	59,318		$	154,584		$	174,805		$	134,112		$	116,619

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details